Hydrocephalus treatment developer CereVasc announced today that it closed an expanded Series A financing round, raising a total of $43.9 million. The Perceptive Xontogeny Venture (PXV) Fund and ATON Partners led the funding round, according to a news release. CereVasc intends to use the raised proceeds to support the first-in-human clinical trial for its eShunt […]
Sunrise Labs executes succession plan | Personnel Moves – April 5, 2018
Medical device and life science development group Sunrise Labs said this week that it completed its succession plan, with president Eric Soederberg acquiring the majority of shares in the company through a stock sale with founder and board chair Drew Sunstein. With the transaction, the Bedford, N.H.-based company said that it secured its planned ownership […]
